← Research ProtocolsSemax
STUDIED EXPOSURE MAP / 2018
Semax
tested in research.
The actual doses, concentrations or exposure levels reported by the source — kept attached to route, population, timeframe and evidence type.
HUMAN / PILOTHUMAN PILOT / EVIDENCE SUMMARYSTUDIED EXPOSURE ≠ RECOMMENDED DOSE
STUDIED EXPOSURE / SOURCE DATANumbers below describe this research source only.
1.2 mg total
intranasal · 1% solution
Context: The primary literature is region-specific and not always easily accessible in English. This map uses a research evidence summary that identifies the 1.2 mg total exposure in the 24-person pilot.
NOT A DOSING GUIDEENHANCED is reporting what researchers administered or tested. It does not convert these numbers into a personal dose, reconstitution plan, cycle, titration schedule or recommendation.
SOURCE / HUMAN PILOT / EVIDENCE SUMMARY
Healthy-volunteer fMRI pilot study summarized by Cognitive Vitality
Study design and tested exposure are separated from recommendation. Route and population stay visible so the numbers cannot be read without context.
2018
01 / DESIGNPlacebo-controlled pilot neuroimaging study
02 / POPULATION / MODEL24 healthy subjects
03 / ROUTEIntranasal · 1% solution
04 / TIMEFRAMEAcute fMRI study
05 / PRIMARY QUESTIONResting-state network signal after administration
It supports a factual statement about the exposure tested in this research source. It does not establish that the same exposure is appropriate, effective or safe outside that source.
Neurobiology and cognitive-signalling research
Study exposure ≠ personal protocol. Animal doses are never converted to human-equivalent amounts here. IV, topical, oral, intranasal and subcutaneous exposures are not treated as interchangeable.